Nattokinase has been shown to degrade fibrin clots both in clot lysis assays comparable to plasmin and by affecting plasminogen activator inhibitor 1 (PAI-1), which is the primary inhibitor of tissue-type plasminogen activator (t-PA).
Human clinical studies have demonstrated the ability of nattokinase to decrease euglobin (clot) lysis time (ELT) up to 8 hours after oral intake of a dose of natto estimated at 6,000 fibrin degradation units (FU). In addition, euglobulin fibrinolytic activity (EFA; lysis area on a fibrin plate) was increased significantly up to 12 hours following administration.
NSK-SD™ is a superior form of Nattokinase
Highest potency available > 20,000 FU/gram (2,000 FU/capsule)
Vitamin K2 - free
Non-GMO, vegan and non-irradiated
Recognized by the JHFA (Japan Health and Nutrition Food Authorization) and the JNKA (Japan Nattokinase Association) as authentic Nattokinase
Contra-Indications: Do not use if you are pregnant or breastfeeding, if you are taking health products that affect blood coagulation, or if you have a bleeding disorder. Consult a health care practitioner if you have a cardiovascular, kidney, or liver disorder. Stop using this product 7 days before any scheduled surgery, or immediately if you have unscheduled surgery or if you suffer from an injury resulting in bruising or bleeding. This product is derived from soy. Do not use if you have soy allergy.